renal cell carcinoma - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

GSK Plc., a British global pharmaceutical company, announced the FDA had approved an oral drug to treat anaemia arising from chronic kidney disease in patients who have been on dialysis for four months.

FDA expands approval of kidney cancer drug to earlier-stage patients

HQ Team June 16, 2026: The US Food and Drug Administration (FDA) has expanded approval of belzutifan, a first-in-class kidney cancer drug, to.

by HealthQuill
June 16, 2026
0 Comments

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment.

Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.